Physician profile
Tadhg Schempf
NPI 1376108092
$3,409.74
in general payments reported to CMS, 2019-2025
12 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 82% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.99 · 2022: $85.10 · 2023: $70.37 · 2024: $952 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.38 | 2024-2025 | |
| Sight Sciences, INC. | $661.00 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $550.90 | 2024-2025 | Vyzulta, Miebo, Zylet |
| New World Medical,INC. | $535.74 | 2024-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Tarsus Pharmaceuticals, INC. | $324.58 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $261.31 | 2022-2025 | Hydrus Microstent, Clareon, Argos |
| Glaukos Corporation | $148.04 | 2022-2025 | Idosetr |
| Allergan, INC. | $99.99 | 2020 | |
| Genentech USA, INC. | $34.55 | 2024 | Vabysmo |
| Harrow Eye, LLC | $29.67 | 2025 | Iheezo |
| Dompe US, INC. | $23.35 | 2024 | Oxervate |
| Astellas Pharma US INC | $20.23 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tadhg Schempf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.